HC Wainwright Has Positive Outlook for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Research analysts at HC Wainwright upped their FY2026 EPS estimates for Protalix BioTherapeutics in a research note issued to investors on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of $0.29 per share for the year, up from their prior forecast of $0.25. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share.

Protalix BioTherapeutics Trading Up 2.2%

Shares of NYSE:PLX opened at $2.73 on Friday. Protalix BioTherapeutics has a twelve month low of $1.60 and a twelve month high of $3.19. The firm has a market cap of $219.96 million, a P/E ratio of -21.00 and a beta of 0.02. The company has a 50 day moving average of $2.43 and a 200-day moving average of $2.33.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. WINTON GROUP Ltd acquired a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth approximately $130,000. Two Sigma Securities LLC acquired a new stake in Protalix BioTherapeutics during the second quarter valued at approximately $41,000. Equitable Holdings Inc. acquired a new stake in Protalix BioTherapeutics during the second quarter valued at approximately $31,000. Bank of America Corp DE bought a new stake in Protalix BioTherapeutics during the second quarter worth approximately $121,000. Finally, Ieq Capital LLC acquired a new position in Protalix BioTherapeutics in the second quarter worth approximately $32,000. Institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.